Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference
Date:6/8/2011

NOVATO, Calif., June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 15, 2011 at 10:00 a.m. CT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin to Present at the Jefferies Global Healthcare Conference
2. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
3. BioMarin Announces First Quarter 2011 Financial Results
4. BioMarin to Present at the Deutsche Bank Healthcare Conference
5. BioMarin to Present at the Barclays Global Healthcare Conference
6. BioMarin to Present at the Cowen Health Care Conference
7. BioMarin to Present at the Citi Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
10. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Research and Markets ... "Stability Testing of Pharmaceuticals (London, UK - December ... By attending this comprehensive two day seminar delegates will: ... studies that are suitable for global arketing - ... manage stability samples and facilities - Know how ...
(Date:9/4/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced its financial results for the fiscal ... of recent Company highlights and expected near-term milestones. ... update conference call and live webcast for investors, analysts ...
(Date:9/3/2015)... Sept. 3, 2015  Cipla, a global pharmaceutical company ... needs of all patients, today announced that its UK ... acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan ... conditions, is valued at $550 million and will be ... transactions is over $200 million for the year ended ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5
... Masimo (NASDAQ: MASI ) ... month,s issue of the peer-reviewed journal, Annals of ... measurements provide an "effective means for screening at-risk populations ... to invasive blood gas analysis.  The prospective diagnostic accuracy ...
... Sanare, LLC, a leading provider of care ... new consumer brand, BrightSky, have become National Strategic ... (Logo: http://photos.prnewswire.com/prnh/20110414/FL83264LOGO) The sponsorship makes Sanare ... Association,s newly diagnosed patient initiative called "Living With ...
Cached Medicine Technology:New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning 2New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning 3New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning 4New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning 5New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning 6Sanare and BrightSky Announce National Strategic Partnership with American Diabetes Association 2
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... 2014, Insight Product Development has effectively doubled the size of its annual health ... Midwest medical device and digital health startups to compete for cash and prizes ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First ... lack of funding for sidewalks, bike paths, and other vital supports severely limit access ... region spends billions of dollars to expand public transit, there’s very little support for ...
(Date:9/4/2015)... ... 2015 , ... The Providence Fertility Center will host a Fertility Cocktail Hour" ... freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and lounge, ... event will discuss the basics of female fertility and egg freezing, and offer women ...
(Date:9/4/2015)... Bogart, GA (PRWEB) , ... September 04, 2015 ... ... serving Bogart and the surrounding communities, is launching a charity effort to provide ... , Commonly referred to as an enlarged heart, restrictive cardiomyopathy often leads to ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... the Consumer Health Products Association (CHPA) joint meeting of its Product, Quality and ... for hazardous waste handling rules constantly evolving in the consumer goods industry, it ...
Breaking Medicine News(10 mins):Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3
... age for screening, which U.S. is pondering, , TUESDAY, July ... support a growing movement to raise the age at which ... , In England, the recommended age at which a woman ... to 25. In the United States, however, women are told ...
... the target for genistein, a dietary compound, in prostate cancer ... in the Journal of the National Cancer Institute . ... of the Department of Medicine at Northwestern University in Chicago, ... cells by assessing cell invasion and gene and protein expression ...
... , , LAS VEGAS, July 28 ... today announced that it will release its Fiscal 2009 third quarter financial results ... invites you to participate in a teleconference to review the financial ... will be held Tuesday, August 4, 2009 at 1:30 p.m. PDT. To access ...
... NEW YORK, July 28 Finding time to treat the "you" in ... Here,s more on a how you can do just that with ... report from Kellogg,s at: , http://inr.mediaseed.tv/oneClip_C/?feed=LRP2yXtJhkA_O5oRbn5PG4L4KgGq7sMi ... text, graphics and photos for free and unrestricted use at ...
... , , , ... Eleven innovative veterinary students from around the ... of companion animals and wildlife. The students, whose projects were ... program, presented posters of their results at MAF,s annual meeting ...
... 28 Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... 30, 2009, an increase of $12.3 million, or 6.8%, from $181.2 ... or 25.4%, to $10.0 million in the second quarter of 2009 ... quarter of 2009 were $0.31 per diluted share compared to pro ...
Cached Medicine News:Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2009 Third Quarter Investor Teleconference 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 3Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 2Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 3Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 5Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 6Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 7Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 8Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 9
... The OraSure HIV-1 Western Blot is ... with an OraSure HIV-1 oral fluid sample. ... with the Oral Fluid Vironostika HIV-1 Microelisa ... HIV-1 Western Blot Kit using the same ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
... HIV-1 Genotyping: The genome of ... in an infected patient, especially in response ... mutations have been shown to render the ... drugs, diminishing the effectiveness of the treatment.,The ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
Medicine Products: